Ductal carcinoma of the prostate is a rare histologic subtype ofprostate carcinoma. It represents 0.4% to 0.8% of all prostatecancers and is associated with a poor prognosis. Given the paucityof cases reported in the literature on ductal prostate carcinoma,little is known about how this cancer responds to cytotoxicchemotherapy. We report the case of a 56-year-old male whopresented to our clinic with hemoptysis, cough and hematuriaand was found to have metastatic ductal carcinoma of the prostate.He was initiated on docetaxel chemotherapy, which has beenpreviously shown to improve overall survival in patients withmetastatic prostate adenocarcinoma, but has never been studiedin this less common subtype of prostate cancer. To the best ofour knowledge, the following is the first reported case of a patientwith metastatic ductal carcinoma of the prostate responding todocetaxel chemotherapy.